CN116323604A - 5-甲基-1,2,4-噁二唑-3-基化合物的低剂量方案和制剂 - Google Patents
5-甲基-1,2,4-噁二唑-3-基化合物的低剂量方案和制剂 Download PDFInfo
- Publication number
- CN116323604A CN116323604A CN202180063288.5A CN202180063288A CN116323604A CN 116323604 A CN116323604 A CN 116323604A CN 202180063288 A CN202180063288 A CN 202180063288A CN 116323604 A CN116323604 A CN 116323604A
- Authority
- CN
- China
- Prior art keywords
- compound
- day
- total dose
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055362P | 2020-07-23 | 2020-07-23 | |
| US63/055,362 | 2020-07-23 | ||
| PCT/US2021/042877 WO2022020663A1 (en) | 2020-07-23 | 2021-07-23 | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116323604A true CN116323604A (zh) | 2023-06-23 |
Family
ID=77338898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180063288.5A Pending CN116323604A (zh) | 2020-07-23 | 2021-07-23 | 5-甲基-1,2,4-噁二唑-3-基化合物的低剂量方案和制剂 |
Country Status (21)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3243602A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110198940A (zh) * | 2017-01-27 | 2019-09-03 | 伊莱利利公司 | 作为oga抑制剂的n-[4-氟-5-[[(2s,4s)-2-甲基-4-[(5-甲基-1,2,4-噁二唑-3-基)甲氧基]-1-哌啶基]甲基]噻唑-2-基]乙酰胺 |
| WO2020028141A1 (en) * | 2018-07-31 | 2020-02-06 | Eli Lilly And Company | Combination therapy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107735190B (zh) * | 2016-07-22 | 2019-11-26 | 深圳市大富科技股份有限公司 | Usb金属管件加工设备及其上模板 |
-
2021
- 2021-07-21 TW TW110126729A patent/TW202220650A/zh unknown
- 2021-07-21 AR ARP210102050A patent/AR123031A1/es unknown
- 2021-07-23 EP EP21755253.8A patent/EP4185291B1/en active Active
- 2021-07-23 CA CA3186808A patent/CA3186808A1/en active Pending
- 2021-07-23 IL IL300023A patent/IL300023A/en unknown
- 2021-07-23 JP JP2023504346A patent/JP2023535034A/ja active Pending
- 2021-07-23 CN CN202180063288.5A patent/CN116323604A/zh active Pending
- 2021-07-23 KR KR1020237005839A patent/KR20230043905A/ko not_active Withdrawn
- 2021-07-23 US US18/005,245 patent/US20230338349A1/en active Pending
- 2021-07-23 ES ES21755253T patent/ES3039536T3/es active Active
- 2021-07-23 WO PCT/US2021/042877 patent/WO2022020663A1/en not_active Ceased
- 2021-07-23 BR BR112023000975A patent/BR112023000975A2/pt unknown
- 2021-07-23 MX MX2023000993A patent/MX2023000993A/es unknown
- 2021-07-23 PH PH1/2023/550177A patent/PH12023550177A1/en unknown
- 2021-07-23 AU AU2021312894A patent/AU2021312894B2/en active Active
- 2021-07-23 PE PE2023000107A patent/PE20231031A1/es unknown
-
2023
- 2023-01-19 CL CL2023000194A patent/CL2023000194A1/es unknown
- 2023-01-19 CO CONC2023/0000594A patent/CO2023000594A2/es unknown
- 2023-01-20 DO DO2023000009A patent/DOP2023000009A/es unknown
- 2023-01-23 EC ECSENADI20235057A patent/ECSP23005057A/es unknown
- 2023-01-23 JO JOJO/P/2023/0018A patent/JOP20230018A1/ar unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110198940A (zh) * | 2017-01-27 | 2019-09-03 | 伊莱利利公司 | 作为oga抑制剂的n-[4-氟-5-[[(2s,4s)-2-甲基-4-[(5-甲基-1,2,4-噁二唑-3-基)甲氧基]-1-哌啶基]甲基]噻唑-2-基]乙酰胺 |
| WO2020028141A1 (en) * | 2018-07-31 | 2020-02-06 | Eli Lilly And Company | Combination therapy |
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023000194A1 (es) | 2023-07-21 |
| EP4185291C0 (en) | 2025-07-09 |
| CA3186808A1 (en) | 2022-01-27 |
| AU2021312894B2 (en) | 2025-09-11 |
| PE20231031A1 (es) | 2023-07-10 |
| IL300023A (en) | 2023-03-01 |
| BR112023000975A2 (pt) | 2023-02-07 |
| KR20230043905A (ko) | 2023-03-31 |
| ES3039536T3 (en) | 2025-10-22 |
| ECSP23005057A (es) | 2023-02-28 |
| AR123031A1 (es) | 2022-10-26 |
| MX2023000993A (es) | 2023-03-01 |
| PH12023550177A1 (en) | 2024-03-18 |
| AU2021312894A1 (en) | 2023-02-23 |
| EP4185291A1 (en) | 2023-05-31 |
| US20230338349A1 (en) | 2023-10-26 |
| JOP20230018A1 (ar) | 2023-01-23 |
| DOP2023000009A (es) | 2023-02-15 |
| CO2023000594A2 (es) | 2023-01-26 |
| WO2022020663A1 (en) | 2022-01-27 |
| EP4185291B1 (en) | 2025-07-09 |
| JP2023535034A (ja) | 2023-08-15 |
| TW202220650A (zh) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Laderian et al. | CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib | |
| JP4938905B2 (ja) | 選択的s1p1レセプターアゴニストの投与法 | |
| EP3730140B1 (en) | Tradipitant for use in treating nausea or vomiting | |
| EP4110326B1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| TWI922768B (zh) | 包含cdk4抑制劑之用於治療癌症之方法及給藥方案 | |
| TW202304424A (zh) | 包含依維莫司和安森司群的組合 | |
| JP2018538273A (ja) | 虚血性脳卒中を処置するための組成物および方法 | |
| JP2017510607A (ja) | S1p調節剤即時放出投与レジメン | |
| Zheng et al. | Randomized, double-blind, placebo-controlled trial of shuanghua baihe tablets to prevent oral mucositis in patients with nasopharyngeal cancer undergoing chemoradiation therapy | |
| WO2004054574A1 (ja) | 経口固形医薬 | |
| JP2018531605A5 (cg-RX-API-DMAC7.html) | ||
| EA028060B1 (ru) | Комбинированная терапия бокового амиотрофического склероза | |
| JP2024539476A5 (cg-RX-API-DMAC7.html) | ||
| KR20160118234A (ko) | 만성 신장병의 진행 억제 또는 개선제 | |
| WO2021140478A1 (en) | Combination therapy for treating cancer | |
| EP4185291B1 (en) | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound | |
| JP6454436B1 (ja) | ペマフィブラートを含有する医薬 | |
| JP2026514040A (ja) | Psmaを標的とする放射性医薬品及びdna損傷応答阻害剤の併用療法 | |
| HK40084518A (en) | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound | |
| HK40084518B (en) | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound | |
| JP6420923B1 (ja) | 医薬 | |
| EA052714B1 (ru) | Фармацевтическая композиция, содержащая производные дифенилдиазола, и способ применения | |
| FI4065134T3 (fi) | Rautasuksinaatin antaminen suun kautta käytettäväksi raudanpuutoksen hoidossa potilailla, joilla on sydämen vajaatoiminta | |
| HK1248552B (en) | Method of treatment with tradipitant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20230623 |